This UV Lamp Could Prevent the Flu Virus From Spreading in Public Places
Researchers have developed an ultraviolet (UV) lamp that kills the influenza virus but isn’t harmful to human skin or eyes, according to a new study in Scientific Reports. They hope the technology can be commercialized and marketed to prevent the spread of seasonal flu in public places, such as schools, hospitals, and airports. “We’ve known for a century that UV light is extremely efficient at killing microbes, bacteria, and viruses,” says study leader David Brenner, director of the Center for Radiological Research at Columbia University Irving Medical Center. For that reason, UV devices are often used for sterilization — for medical equipment in hospitals, for example, or drinking water for backcountry campers. But conventional germicidal lamps aren’t safe for humans to be around. With prolonged exposure, they can cause skin cancer and cataracts in the eyes. “So up until now, they’re only really practical when people aren’t around,” say Brenner. “You can sterilize a hospital room, but not when anyone’s inside.” About five years ago, Brenner says, the Columbia team came up with a potential solution. Light on the far end of the UV-C spectrum, known as far-UVC, has very short wavelengths. The researchers suspected that it can penetrate and destroy microscopic bacteria and viruses, but can’t travel through the protective outer layers of human skin or eyes. “We wanted to get all the benefit...
Conclusions: These results suggest that JAK/STAT3 and NF-κB signals play important roles in ATC-CSCs. Targeting these signaling pathways may be a promising approach to treat ATC. PMID: 30784360 [PubMed - as supplied by publisher]
The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans.
Geoffrey Turner, 66, of Latham, New York, passed away on February 13 after a three-month battle with lung cancer. His self-deprecating obituary appeared in the Albany Times-Union on Saturday.
CONCLUSIONS: Poorer humoral immune responses to PPSV-23 as measured by fold change were more likely to be observed in subjects with asthma compared to controls. We recommend the consideration of asthma status when interpreting vaccine response for immune competence workup through larger studies. Further studies are warranted to replicate these findings. PMID: 30784333 [PubMed - as supplied by publisher]
In a reverse decision, the World Health Organization (WHO) now recommends vaccinating pregnant and breastfeeding women against the Ebola virus.
Authors: De Luca L, Laurenzana I, Trino S, Lamorte D, Caivano A, Musto P Abstract INTRODUCTION: Multiple myeloma (MM) is characterized by a clonal proliferation of neoplastic plasma cells (PCs) in bone marrow (BM) and the interplay between MM PCs and the BM microenvironment, which plays a relevant role in its pathogenesis. In this important cross-talk, extracellular vesicles (EVs) are active. EVs, including small and medium/large EVs, are lipid bi-layer particles released in circulation by normal and neoplastic cells. A selected cargo of lipids, proteins, and nucleic acids is loaded into EVs, and delivered locally ...
Investigational agent sacituzumab govitecan showed activity in patients with metastatic urothelial cancer, including some previously treated with immune checkpoint inhibitors.Medscape Medical News
We report means and 95% uncertainty intervals (UIs) for incidence, mortality, and disability-adjusted life-years (DALYs) estimates for CNS cancers (according to the International Classification of Diseases tenth revision: malignant neoplasm of meninges, malignant neoplasm of brain, and malignant neoplasm of spinal cord, cranial nerves, and other parts of CNS) from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016. Data sources include vital registration and cancer registry data. Mortality was modelled using an ensemble model approach. Incidence was estimated by dividing the final mortality estimates by m...
Authors: Adamo B, Ricciardi GRR, Ieni A, Franchina T, Fazzari C, Sanò MV, Angelico G, Caruso M, Tuccari G, Adamo V Abstract [This corrects the article DOI: 10.18632/oncotarget.20293.]. PMID: 30783520 [PubMed - in process]
Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. Oncotarget. 2019 Jan 25;10(8):916 Authors: Trošt N, Peña-Llopis S, Koirala S, Stojan J, Potts PR, Fon Tacer K, Martinez ED Abstract [This corrects the article DOI: 10.18632/oncotarget.6006.]. PMID: 30783519 [PubMed - in process]
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cataract Removal | Cataracts | Epidemics | Epidemiology | Eyes | H1N1 | Health | Hospitals | Infectious Diseases | Influenza | Influenza Vaccine | Medical Devices | MRSA | Schools | Skin | Skin Cancer | Study | Superbugs | Swine Flu (H1N1) Vaccine | Vaccines | Veterinary Vaccinations